HiST Pharma

Executive Summary

HiST Pharma is a privately held biotechnology company headquartered in Chengdu, China, founded in 2016 with a focus on oncology. The company employs a diversified drug discovery approach, targeting complex diseases through both small molecule and biologic modalities. Its research efforts aim to identify novel compounds with improved therapeutic indices, though specific pipeline details are not publicly disclosed. As a preclinical-stage company with fewer than 50 employees, HiST Pharma operates in the competitive Chinese biotech landscape, leveraging local scientific talent and potentially benefiting from regional regulatory support. Given its early stage, HiST Pharma faces significant development and funding risks. The company has not reported any clinical milestones or financing rounds, making its valuation challenging to assess. However, its multimodal strategy could provide multiple shots on goal if lead candidates advance. Near-term catalysts may include progress toward an Investigational New Drug (IND) application, a Series A or B financing round, or a strategic partnership. With no public data on its pipeline, conviction remains low, but the company's diversified approach warrants monitoring for upcoming inflection points.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate40% success
• H1 2027Series B Financing Round50% success
• 2027Strategic Partnership or Licensing Deal30% success